TY - JOUR AU - Baum, C. AU - Kirschmeier, P. PY - 2003 DA - 2003// TI - Preclinical and clinical evaluation of farnesyltransferase inhibitors JO - Curr Oncol Rep VL - 5 UR - https://doi.org/10.1007/s11912-003-0096-5 DO - 10.1007/s11912-003-0096-5 ID - Baum2003 ER - TY - JOUR AU - End, D. W. AU - Smets, G. AU - Todd, A. V. AU - Applegate, T. L. AU - Fuery, C. J. AU - Angibaud, P. AU - Venet, M. AU - Sanz, G. AU - Poignet, H. AU - Skrzat, S. PY - 2001 DA - 2001// TI - Characterization of the antitumour effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro JO - Cancer Res VL - 61 ID - End2001 ER - TY - JOUR AU - de Bono, J. S. AU - Tolcher, A. W. AU - Rowinsky, E. K. PY - 2003 DA - 2003// TI - Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma JO - Semin Oncol VL - 30 UR - https://doi.org/10.1053/j.seminoncol.2003.08.010 DO - 10.1053/j.seminoncol.2003.08.010 ID - de Bono2003 ER - TY - JOUR AU - Schiff, R. AU - Massarweh, S. AU - Shou, J. AU - Osborne, C. K. PY - 2003 DA - 2003// TI - Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response JO - Clin Cancer Res VL - 9 ID - Schiff2003 ER - TY - JOUR AU - De Medina, P. AU - Favre, G. AU - Poirot, M. PY - 2004 DA - 2004// TI - Multiple targeting by the antitumour drug tamoxifen: a structure-activity study JO - Curr Med Chem Anti-Canc Agents VL - 4 UR - https://doi.org/10.2174/1568011043352696 DO - 10.2174/1568011043352696 ID - De Medina2004 ER - TY - JOUR AU - Sutherland, R. L. AU - Murphy, L. C. AU - San Foo, M. AU - Green, M. D. AU - Whybourne, A. M. AU - Krozowski, Z. S. PY - 1980 DA - 1980// TI - High-affinity anti-oestrogen binding site distinct from the oestrogen receptor JO - Nature VL - 288 UR - https://doi.org/10.1038/288273a0 DO - 10.1038/288273a0 ID - Sutherland1980 ER - TY - JOUR AU - Faye, J. C. AU - Jozan, S. AU - Redeuilh, G. AU - Baulieu, E. E. AU - Bayard, F. PY - 1983 DA - 1983// TI - Physicochemical and genetic evidence for specific anti-estrogen binding sites JO - Proc Natl Acad Sci USA VL - 80 UR - https://doi.org/10.1073/pnas.80.11.3158 DO - 10.1073/pnas.80.11.3158 ID - Faye1983 ER - TY - JOUR AU - Kedjouar, B. AU - De Medina, P. AU - Oulad-Abdelghani, M. AU - Payre, B. AU - Silvente-Poirot, S. AU - Favre, G. AU - Faye, J. C. AU - Poirot, M. PY - 2004 DA - 2004// TI - Molecular characterization of the microsomal tamoxifen binding site JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.M405230200 DO - 10.1074/jbc.M405230200 ID - Kedjouar2004 ER - TY - JOUR AU - Sutherland, R. L. AU - Hall, R. E. AU - Taylor, I. W. PY - 1983 DA - 1983// TI - Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells JO - Cancer Res VL - 43 ID - Sutherland1983 ER - TY - JOUR AU - Delarue, F. AU - Kedjouar, B. AU - Mesange, F. AU - Bayard, F. AU - Faye, J. C. AU - Poirot, M. PY - 1999 DA - 1999// TI - Modifications of benzylphenoxy ethanamine anti-estrogen molecules: influence affinity for anti-estrogen binding site (AEBS) and cell cytotoxicity JO - Biochem Pharmacol VL - 57 UR - https://doi.org/10.1016/S0006-2952(98)00347-5 DO - 10.1016/S0006-2952(98)00347-5 ID - Delarue1999 ER - TY - JOUR AU - Mandlekar, S. AU - Yu, R. AU - Tan, T. H. AU - Kong, A. N. PY - 2000 DA - 2000// TI - Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells JO - Cancer Res VL - 60 ID - Mandlekar2000 ER - TY - JOUR AU - Mandlekar, S. AU - Hebbar, V. AU - Christov, K. AU - Kong, A. N. PY - 2000 DA - 2000// TI - Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumours and in human breast cancer cell lines JO - Cancer Res VL - 60 ID - Mandlekar2000 ER - TY - JOUR AU - Tamanoi, F. AU - Gau, C. L. AU - Jiang, C. AU - Edamatsu, H. AU - Kato-Stankiewicz, J. PY - 2001 DA - 2001// TI - Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells JO - Cell Mol Life Sci VL - 58 UR - https://doi.org/10.1007/PL00000802 DO - 10.1007/PL00000802 ID - Tamanoi2001 ER - TY - JOUR AU - Doisneau-Sixou, S. F. AU - Cestac, P. AU - Faye, J. C. AU - Favre, G. AU - Sutherland, R. L. PY - 2003 DA - 2003// TI - Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression JO - Int J Cancer VL - 106 UR - https://doi.org/10.1002/ijc.11263 DO - 10.1002/ijc.11263 ID - Doisneau-Sixou2003 ER - TY - JOUR AU - Doisneau-Sixou, S. F. AU - Cestac, P. AU - Chouini, S. AU - Carroll, J. S. AU - Hamilton, A. D. AU - Sebti, S. M. AU - Poirot, M. AU - Balaguer, P. AU - Faye, J. C. AU - Sutherland, R. L. PY - 2003 DA - 2003// TI - Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells JO - Endocrinology VL - 144 UR - https://doi.org/10.1210/en.2002-220726 DO - 10.1210/en.2002-220726 ID - Doisneau-Sixou2003 ER - TY - JOUR AU - Poirot, M. AU - De Medina, P. AU - Delarue, F. AU - Perie, J. J. AU - Klaebe, A. AU - Faye, J. C. PY - 2000 DA - 2000// TI - Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS) JO - Bioorg Med Chem VL - 8 UR - https://doi.org/10.1016/S0968-0896(00)00119-X DO - 10.1016/S0968-0896(00)00119-X ID - Poirot2000 ER - TY - JOUR AU - Skehan, P. AU - Storeng, R. AU - Scudiero, D. AU - Monks, A. AU - McMahon, J. AU - Vistica, D. AU - Warren, J. T. AU - Bokesch, H. AU - Kenney, S. AU - Boyd, M. R. PY - 1990 DA - 1990// TI - New colorimetric cytotoxicity assay for anticancer-drug screening JO - J Natl Cancer Inst VL - 82 UR - https://doi.org/10.1093/jnci/82.13.1107 DO - 10.1093/jnci/82.13.1107 ID - Skehan1990 ER - TY - JOUR AU - Steel, G. G. AU - Peckham, M. J. PY - 1979 DA - 1979// TI - Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity JO - Int J Radiat Oncol Biol Phys VL - 5 UR - https://doi.org/10.1016/0360-3016(79)90044-0 DO - 10.1016/0360-3016(79)90044-0 ID - Steel1979 ER - TY - JOUR AU - Brandes, L. J. PY - 1984 DA - 1984// TI - A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological role JO - Biochem Biophys Res Commun VL - 124 UR - https://doi.org/10.1016/0006-291X(84)90943-4 DO - 10.1016/0006-291X(84)90943-4 ID - Brandes1984 ER - TY - CHAP AU - De Medina, P. AU - Payre, B. L. AU - Bernad, J. AU - Bosser, I. AU - Pipy, B. AU - Silvente-Poirot, S. AU - Favre, G. AU - Faye, J. C. AU - Poirot, M. E. PY - 2003 DA - 2003// TI - Tamoxifen is a potent inhibitor of cholesterol esterification and prevent the formation of foam cells BT - J Pharmacol Exp Ther ID - De Medina2003 ER - TY - JOUR AU - Ellis, C. A. AU - Vos, M. D. AU - Wickline, M. AU - Riley, C. AU - Vallecorsa, T. AU - Telford, W. G. AU - Zujewskil, J. AU - Clark, G. J. PY - 2003 DA - 2003// TI - Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumour cell lines JO - Breast Cancer Res Treat VL - 78 UR - https://doi.org/10.1023/A:1022105511409 DO - 10.1023/A:1022105511409 ID - Ellis2003 ER - TY - JOUR AU - Bompard, G. AU - Puech, C. AU - Prebois, C. AU - Vignon, F. AU - Freiss, G. PY - 2002 DA - 2002// TI - Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M208950200 DO - 10.1074/jbc.M208950200 ID - Bompard2002 ER - TY - JOUR AU - Edamatsu, H. AU - Gau, C. L. AU - Nemoto, T. AU - Guo, L. AU - Tamanoi, F. PY - 2000 DA - 2000// TI - Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1203625 DO - 10.1038/sj.onc.1203625 ID - Edamatsu2000 ER - TY - JOUR AU - Di Croce, L. AU - Vicent, G. P. AU - Pecci, A. AU - Bruscalupi, G. AU - Trentalance, A. AU - Beato, M. PY - 1999 DA - 1999// TI - The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region JO - Mol Endocrinol VL - 13 UR - https://doi.org/10.1210/mend.13.8.0333 DO - 10.1210/mend.13.8.0333 ID - Di Croce1999 ER - TY - CHAP AU - Kedjouar, B. AU - De Medina, P. AU - Faye, J. C. AU - Poirot, M. PY - 2001 DA - 2001// TI - Induction of apoptosis in human mammary carcinoma cells by (4-cumyl-phenoxy)-ethyl-N-pyrrolidine-HCl BT - 92nd Annual Meeting of the Proceedings of the American Association for Cancer Research: March 24–28 2001; New Orleans ID - Kedjouar2001 ER - TY - JOUR AU - Lebowitz, P. F. AU - Eng-Wong, J. AU - Widemann, B. C. AU - Balis, F. M. AU - Jayaprakash, N. AU - Chow, C. AU - Clark, G. AU - Gantz, S. B. AU - Venzon, D. AU - Zujewski, J. PY - 2005 DA - 2005// TI - A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer JO - Clin Cancer Res VL - 11 ID - Lebowitz2005 ER - TY - JOUR AU - Head, J. AU - Johnston, S. R. PY - 2004 DA - 2004// TI - New targets for therapy in breast cancer: farnesyltransferase inhibitors JO - Breast Cancer Res VL - 6 UR - https://doi.org/10.1186/bcr947 DO - 10.1186/bcr947 ID - Head2004 ER - TY - JOUR AU - Reyno, L. AU - Seymour, L. AU - Tu, D. AU - Dent, S. AU - Gelmon, K. AU - Walley, B. AU - Pluzanska, A. AU - Gorbunova, V. AU - Garin, A. AU - Jassem, J. PY - 2004 DA - 2004// TI - Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19 JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2003.04.075 DO - 10.1200/JCO.2003.04.075 ID - Reyno2004 ER -